| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis
|
Hobart, Jeremy
|
|
2013
|
|
13 |
p. 1773-1783
|
artikel
|
| 2 |
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment
|
Graf, Jonas
|
|
2018
|
|
13 |
p. 1776-1778
|
artikel
|
| 3 |
A decline in cognitive function should lead to a change in disease-modifying therapy – Commentary
|
Amato, Maria Pia
|
|
2018
|
|
13 |
p. 1685-1686
|
artikel
|
| 4 |
A decline in cognitive function should lead to a change in disease-modifying therapy – No
|
Portaccio, Emilio
|
|
2018
|
|
13 |
p. 1683-1684
|
artikel
|
| 5 |
A decline in cognitive function should lead to a change in disease-modifying therapy – Yes
|
Weinstock-Guttman, Bianca
|
|
2018
|
|
13 |
p. 1681-1682
|
artikel
|
| 6 |
Adherence in multiple sclerosis (ADAMS): Classification, relevance, and research needs. A meeting report
|
Heesen, Christoph
|
|
2014
|
|
13 |
p. 1795-1798
|
artikel
|
| 7 |
Age is a critical determinant in recovery from multiple sclerosis relapses
|
Conway, Brittani L
|
|
2019
|
|
13 |
p. 1754-1763
|
artikel
|
| 8 |
Alternative data sources for estimating multiple sclerosis prevalence
|
Koch-Henriksen, Nils
|
|
2013
|
|
13 |
p. 1682-1683
|
artikel
|
| 9 |
An adverse lipid profile is associated with disability and progression in disability, in people with MS
|
Tettey, Prudence
|
|
2014
|
|
13 |
p. 1737-1744
|
artikel
|
| 10 |
A NOTCH4 missense mutation confers resistance to multiple sclerosis in Japanese
|
Huang, Jian
|
|
2013
|
|
13 |
p. 1696-1703
|
artikel
|
| 11 |
A novel method for calculating prevalence of multiple sclerosis in Australia
|
Palmer, Andrew J
|
|
2013
|
|
13 |
p. 1704-1711
|
artikel
|
| 12 |
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders
|
Mealy, Maureen A
|
|
2018
|
|
13 |
p. 1737-1742
|
artikel
|
| 13 |
A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients
|
Zivadinov, Robert
|
|
2016
|
|
13 |
p. 1709-1718
|
artikel
|
| 14 |
Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS
|
Capra, Ruggero
|
|
2017
|
|
13 |
p. 1757-1761
|
artikel
|
| 15 |
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis
|
Healy, Brian C
|
|
2019
|
|
13 |
p. 1791-1799
|
artikel
|
| 16 |
Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis
|
Bose, Gauruv
|
|
2019
|
|
13 |
p. 1764-1772
|
artikel
|
| 17 |
Beyond the band: A biomarker for pediatric MS?
|
Chitnis, Tanuja
|
|
2018
|
|
13 |
p. 1655-1656
|
artikel
|
| 18 |
Biotin in progressive multiple sclerosis: A new lead?
|
Chataway, Jeremy
|
|
2016
|
|
13 |
p. 1640-1641
|
artikel
|
| 19 |
Characterizing cognitive function during relapse in multiple sclerosis
|
Benedict, Ralph HB
|
|
2014
|
|
13 |
p. 1745-1752
|
artikel
|
| 20 |
Childhood obesity is a risk factor for multiple sclerosis
|
Munger, Kassandra L
|
|
2013
|
|
13 |
p. 1800-1800
|
artikel
|
| 21 |
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta
|
Giovannoni, Gavin
|
|
2018
|
|
13 |
p. 1725-1736
|
artikel
|
| 22 |
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea
|
Seok, Jin Myoung
|
|
2017
|
|
13 |
p. 1748-1756
|
artikel
|
| 23 |
Clinical commentary on “Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis” and “Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients”
|
Pareés, Isabel
|
|
2017
|
|
13 |
p. 1797-1798
|
artikel
|
| 24 |
Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies
|
Sepúlveda, Maria
|
|
2018
|
|
13 |
p. 1753-1759
|
artikel
|
| 25 |
Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents – Commentary
|
Hintzen, Rogier
|
|
2016
|
|
13 |
p. 1653-1654
|
artikel
|
| 26 |
Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents – NO
|
Francisco, Carla
|
|
2016
|
|
13 |
p. 1651-1653
|
artikel
|
| 27 |
Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents – YES
|
Banwell, Brenda
|
|
2016
|
|
13 |
p. 1649-1651
|
artikel
|
| 28 |
Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis
|
Tobyne, Sean M
|
|
2018
|
|
13 |
p. 1687-1695
|
artikel
|
| 29 |
Cognitive impairment in patients with multiple sclerosis predicts worse caregiver’s health-related quality of life
|
Labiano-Fontcuberta, Andrés
|
|
2014
|
|
13 |
p. 1769-1779
|
artikel
|
| 30 |
Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity
|
Raats, Joke
|
|
2019
|
|
13 |
p. 1736-1745
|
artikel
|
| 31 |
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis
|
Teunissen, Charlotte
|
|
2013
|
|
13 |
p. 1802-1809
|
artikel
|
| 32 |
Corrigendum
|
|
|
2017
|
|
13 |
p. NP30
|
artikel
|
| 33 |
Defining active progressive multiple sclerosis
|
Sellebjerg, Finn
|
|
2017
|
|
13 |
p. 1727-1735
|
artikel
|
| 34 |
Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study
|
Faivre, Anthony
|
|
2016
|
|
13 |
p. 1695-1708
|
artikel
|
| 35 |
Determinants of iron accumulation in deep grey matter of multiple sclerosis patients
|
Ropele, Stefan
|
|
2014
|
|
13 |
p. 1692-1698
|
artikel
|
| 36 |
Diet quality and risk of multiple sclerosis in two cohorts of US women
|
Rotstein, Dalia L
|
|
2019
|
|
13 |
p. 1773-1780
|
artikel
|
| 37 |
Early predictors of multiple sclerosis after a typical clinically isolated syndrome
|
Ruet, Aurélie
|
|
2014
|
|
13 |
p. 1721-1726
|
artikel
|
| 38 |
e-Health and multiple sclerosis: An update
|
Lavorgna, Luigi
|
|
2018
|
|
13 |
p. 1657-1664
|
artikel
|
| 39 |
Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors
|
Krause, Ivonne
|
|
2013
|
|
13 |
p. 1792-1799
|
artikel
|
| 40 |
Environmental factors acting during development to influence MS risk: insights from animal studies
|
Krementsov, Dimitry N
|
|
2013
|
|
13 |
p. 1684-1689
|
artikel
|
| 41 |
Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary
|
Hutchinson, Michael
|
|
2013
|
|
13 |
p. 1694-1695
|
artikel
|
| 42 |
Epstein–Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No
|
Salzer, Jonatan
|
|
2013
|
|
13 |
p. 1692-1693
|
artikel
|
| 43 |
Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Yes
|
Pakpoor, Julia
|
|
2013
|
|
13 |
p. 1690-1691
|
artikel
|
| 44 |
Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
|
Ahmad, Hasnat
|
|
2019
|
|
13 |
p. 1800-1808
|
artikel
|
| 45 |
Fatigue in multiple sclerosis: The contribution of occult white matter damage
|
Bisecco, Alvino
|
|
2016
|
|
13 |
p. 1676-1684
|
artikel
|
| 46 |
Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization
|
Bisecco, Alvino
|
|
2018
|
|
13 |
p. 1696-1705
|
artikel
|
| 47 |
Fingolimod-induced asthma deterioration in a patient with relapsing–remitting multiple sclerosis
|
van Rossum, JA
|
|
2014
|
|
13 |
p. 1792-1793
|
artikel
|
| 48 |
Fluid biomarkers for disease activity in multiple sclerosis
|
Zetterberg, Henrik
|
|
2017
|
|
13 |
p. 1660-1661
|
artikel
|
| 49 |
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial
|
Cambron, Melissa
|
|
2019
|
|
13 |
p. 1728-1735
|
artikel
|
| 50 |
Gender identity disorders and multiple sclerosis risk: A national record-linkage study
|
Pakpoor, Julia
|
|
2016
|
|
13 |
p. 1759-1762
|
artikel
|
| 51 |
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation
|
Hilven, Kelly
|
|
2018
|
|
13 |
p. 1773-1775
|
artikel
|
| 52 |
Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis
|
Zhou, Yuan
|
|
2016
|
|
13 |
p. 1655-1664
|
artikel
|
| 53 |
Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population
|
Ikram, Mohammad Arfan
|
|
2017
|
|
13 |
p. 1697-1706
|
artikel
|
| 54 |
High prevalence and no latitude gradient of multiple sclerosis in Norway
|
Berg-Hansen, P
|
|
2014
|
|
13 |
p. 1780-1782
|
artikel
|
| 55 |
Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue
|
Pravatà, Emanuele
|
|
2016
|
|
13 |
p. 1665-1675
|
artikel
|
| 56 |
Immunomodulatory therapies delay disease progression in multiple sclerosis
|
Bergamaschi, Roberto
|
|
2016
|
|
13 |
p. 1732-1740
|
artikel
|
| 57 |
Immunotherapies and influenza vaccination
|
Joob, Beuy
|
|
2014
|
|
13 |
p. 1794-1794
|
artikel
|
| 58 |
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis
|
Beesley, Rebecca
|
|
2018
|
|
13 |
p. 1786-1787
|
artikel
|
| 59 |
Impairment of decision-making in multiple sclerosis: A neuroeconomic approach
|
Sepúlveda, Maria
|
|
2017
|
|
13 |
p. 1762-1771
|
artikel
|
| 60 |
Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting
|
Jalkanen, A
|
|
2013
|
|
13 |
p. 1734-1742
|
artikel
|
| 61 |
Interferon beta treatment of multiple sclerosis increases serum interleukin-7
|
Lundström, Wangko
|
|
2014
|
|
13 |
p. 1727-1736
|
artikel
|
| 62 |
International consensus on quality standards for brain health-focused care in multiple sclerosis
|
Hobart, Jeremy
|
|
2019
|
|
13 |
p. 1809-1818
|
artikel
|
| 63 |
Labour-associated increase in C-reactive protein concentration is not predictive of postpartum relapse activity among mothers with multiple sclerosis
|
Jalkanen, Anna
|
|
2014
|
|
13 |
p. 1790-1791
|
artikel
|
| 64 |
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis
|
Nerrant, Elodie
|
|
2014
|
|
13 |
p. 1699-1703
|
artikel
|
| 65 |
Letter to the editor: FLOUX-PMS study sample considerations
|
Grech, Lisa B
|
|
2019
|
|
13 |
p. 1819-1820
|
artikel
|
| 66 |
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
|
Tourbah, Ayman
|
|
2016
|
|
13 |
p. 1719-1731
|
artikel
|
| 67 |
Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis
|
Cameron, Michelle H
|
|
2017
|
|
13 |
p. 1799-1801
|
artikel
|
| 68 |
miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands
|
Quintana, Ester
|
|
2017
|
|
13 |
p. 1716-1726
|
artikel
|
| 69 |
MS Research Australia Progress in MS Research 2017
|
|
|
2017
|
|
13 |
p. NP1-NP29
|
artikel
|
| 70 |
Multiple sclerosis disease progression: Contributions from a hypoxia–inflammation cycle
|
Yang, Runze
|
|
2019
|
|
13 |
p. 1715-1718
|
artikel
|
| 71 |
Neuromodulation in multiple sclerosis
|
Abboud, Hesham
|
|
2017
|
|
13 |
p. 1663-1676
|
artikel
|
| 72 |
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
|
Kappos, Ludwig
|
|
2017
|
|
13 |
p. 1736-1747
|
artikel
|
| 73 |
Observational data: Understanding the real MS world
|
Kalincik, Tomas
|
|
2016
|
|
13 |
p. 1642-1648
|
artikel
|
| 74 |
Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
|
Harrison, Anthony Mark
|
|
2017
|
|
13 |
p. 1682-1696
|
artikel
|
| 75 |
Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis
|
Lanzillo, Roberta
|
|
2018
|
|
13 |
p. 1706-1714
|
artikel
|
| 76 |
Paroxysmal kinesigenic dyskinesia–like phenotype in multiple sclerosis
|
Pop, Roxana
|
|
2017
|
|
13 |
p. 1795-1797
|
artikel
|
| 77 |
Perfusion reduction in the absence of structural differences in cognitively impaired versus unimpaired RRMS patients
|
Hojjat, Seyed-Parsa
|
|
2016
|
|
13 |
p. 1685-1694
|
artikel
|
| 78 |
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis
|
Hollingworth, Samantha
|
|
2013
|
|
13 |
p. 1712-1716
|
artikel
|
| 79 |
Physician-assisted death should be available to people with MS – Commentary
|
Coles, Alasdair
|
|
2017
|
|
13 |
p. 1681
|
artikel
|
| 80 |
Physician-assisted death should be available to people with MS – No
|
Scolding, Neil
|
|
2017
|
|
13 |
p. 1679-1680
|
artikel
|
| 81 |
Physician-assisted death should be available to people with MS – YES
|
Wiebe, Kim Louise
|
|
2017
|
|
13 |
p. 1677-1678
|
artikel
|
| 82 |
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy
|
Tateo, Fabio
|
|
2019
|
|
13 |
p. 1719-1727
|
artikel
|
| 83 |
Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis
|
Kupersmith, Mark J
|
|
2013
|
|
13 |
p. 1743-1748
|
artikel
|
| 84 |
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod
|
Hoepner, Robert
|
|
2014
|
|
13 |
p. 1714-1720
|
artikel
|
| 85 |
Predictors of outcome in a large retrospective cohort of patients with transverse myelitis
|
Gastaldi, Matteo
|
|
2018
|
|
13 |
p. 1743-1752
|
artikel
|
| 86 |
Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis
|
Leavitt, Victoria M
|
|
2017
|
|
13 |
p. 1786-1790
|
artikel
|
| 87 |
Recommendations for cognitive screening and management in multiple sclerosis care
|
Kalb, Rosalind
|
|
2018
|
|
13 |
p. 1665-1680
|
artikel
|
| 88 |
Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial
|
Charvet, Leigh E
|
|
2018
|
|
13 |
p. 1760-1769
|
artikel
|
| 89 |
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy
|
Achiron, Anat
|
|
2019
|
|
13 |
p. 1746-1753
|
artikel
|
| 90 |
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening
|
Phillips, Glenn A
|
|
2014
|
|
13 |
p. 1753-1760
|
artikel
|
| 91 |
Response to de Groot ‘There is an urgent need for palliative care specialists in MS – Commentary’
|
Cheong, Wing Loong
|
|
2019
|
|
13 |
p. 1821-1822
|
artikel
|
| 92 |
Response to Grech et al.: FLOUX-PMS study sample considerations
|
Mostert, Jop P
|
|
2019
|
|
13 |
p. 1820-1821
|
artikel
|
| 93 |
Response to letter from Dr KL Munger, ‘Childhood obesity is a risk factor for multiple sclerosis’
|
Ponsonby, Anne-Louise
|
|
2013
|
|
13 |
p. 1801-1801
|
artikel
|
| 94 |
Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria
|
Tantsis, Esther M
|
|
2013
|
|
13 |
p. 1749-1759
|
artikel
|
| 95 |
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ
|
Pfeuffer, Steffen
|
|
2018
|
|
13 |
p. 1783-1784
|
artikel
|
| 96 |
Sarcoidosis following alemtuzumab treatment for multiple sclerosis
|
Willis, Mark D
|
|
2018
|
|
13 |
p. 1779-1782
|
artikel
|
| 97 |
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical–radiological features and treatment. Case report of seven patients
|
Ciampi, Ethel
|
|
2017
|
|
13 |
p. 1791-1795
|
artikel
|
| 98 |
Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis
|
Van Haren, Keith
|
|
2013
|
|
13 |
p. 1726-1733
|
artikel
|
| 99 |
Similar familial risk in multiple sclerosis subgroups
|
Song, Jie
|
|
2017
|
|
13 |
p. 1782-1785
|
artikel
|
| 100 |
Smokers with MS have greater decrements in quality of life and disability than non-smokers
|
Briggs, Farren BS
|
|
2017
|
|
13 |
p. 1772-1781
|
artikel
|
| 101 |
Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary
|
Hutchinson, Michael
|
|
2014
|
|
13 |
p. 1690-1691
|
artikel
|
| 102 |
Spinal cord MRI should always be performed in clinically isolated syndrome patients: No
|
Rovira, Alex
|
|
2014
|
|
13 |
p. 1686-1687
|
artikel
|
| 103 |
Spinal cord MRI should always be performed in clinically isolated syndrome patients: Yes
|
Barkhof, Frederik
|
|
2014
|
|
13 |
p. 1688-1689
|
artikel
|
| 104 |
Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod
|
Froehlich, Anne
|
|
2018
|
|
13 |
p. 1785-1787
|
artikel
|
| 105 |
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis
|
Strober, Lauren
|
|
2019
|
|
13 |
p. 1781-1790
|
artikel
|
| 106 |
T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes
|
Wong, Yu Yi M
|
|
2018
|
|
13 |
p. 1715-1724
|
artikel
|
| 107 |
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis
|
Pastò, Luisa
|
|
2016
|
|
13 |
p. 1741-1749
|
artikel
|
| 108 |
The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis
|
Lúcio, AC
|
|
2014
|
|
13 |
p. 1761-1768
|
artikel
|
| 109 |
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study
|
Lacy, Maureen
|
|
2013
|
|
13 |
p. 1765-1772
|
artikel
|
| 110 |
The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials
|
Chataway, Jeremy
|
|
2019
|
|
13 |
p. 1697-1699
|
artikel
|
| 111 |
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis
|
Barkhof, Frederik
|
|
2014
|
|
13 |
p. 1704-1713
|
artikel
|
| 112 |
The magnetic resonance imaging ‘rule of five’: predicting the occurrence of relapse
|
Morgan, Charity J
|
|
2013
|
|
13 |
p. 1760-1764
|
artikel
|
| 113 |
The NAIMS cooperative pilot project: Design, implementation and future directions
|
Oh, Jiwon
|
|
2018
|
|
13 |
p. 1770-1772
|
artikel
|
| 114 |
The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study
|
Ponsonby, Anne-Louise
|
|
2013
|
|
13 |
p. 1717-1725
|
artikel
|
| 115 |
There is an urgent need for palliative care specialists in MS – Commentary
|
de Groot, Vincent
|
|
2019
|
|
13 |
p. 1713-1714
|
artikel
|
| 116 |
There is an urgent need for palliative care specialists in MS – No
|
Vanopdenbosch, Ludo J
|
|
2019
|
|
13 |
p. 1712-1713
|
artikel
|
| 117 |
There is an urgent need for palliative care specialists in MS – Yes
|
Solari, Alessandra
|
|
2019
|
|
13 |
p. 1710-1711
|
artikel
|
| 118 |
The relationship of age with the clinical phenotype in multiple sclerosis
|
Scalfari, A
|
|
2016
|
|
13 |
p. 1750-1758
|
artikel
|
| 119 |
The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis
|
Learmonth, Yvonne C
|
|
2013
|
|
13 |
p. 1784-1791
|
artikel
|
| 120 |
The Scandinavian paradox revisited: Editorial comment on Berg-Hansen et al. ‘High prevalence and no latitude gradient of multiple sclerosis in Norway’
|
Simpson, Steve
|
|
2014
|
|
13 |
p. 1675-1677
|
artikel
|
| 121 |
The visual pathway as a model to understand brain damage in multiple sclerosis
|
Martínez-Lapiscina, E H
|
|
2014
|
|
13 |
p. 1678-1685
|
artikel
|
| 122 |
Three-dimensional MRI sequences in MS diagnosis and research
|
Hu, Xun Yang
|
|
2019
|
|
13 |
p. 1700-1709
|
artikel
|
| 123 |
Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing–remitting multiple sclerosis patients on high-dose interferon beta
|
Arrambide, Georgina
|
|
2014
|
|
13 |
p. 1788-1789
|
artikel
|
| 124 |
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β
|
Larochelle, Catherine
|
|
2014
|
|
13 |
p. 1783-1787
|
artikel
|
| 125 |
Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes
|
Cristofanilli, Massimiliano
|
|
2017
|
|
13 |
p. 1707-1715
|
artikel
|
Tijdschrift beschrijving